Pharsight

Beleodaq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6888027 ACROTECH Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
Aug, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(3 years from now)

Beleodaq is owned by Acrotech.

Beleodaq contains Belinostat.

Beleodaq has a total of 2 drug patents out of which 0 drug patents have expired.

Beleodaq was authorised for market use on 03 July, 2014.

Beleodaq is available in powder;intravenous dosage forms.

Beleodaq can be used as treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl)..

The generics of Beleodaq are possible to be released after 27 October, 2027.

Drugs and Companies using BELINOSTAT ingredient

Market Authorisation Date: 03 July, 2014

Treatment: Treatment of patients with relapsed or refractory peripheral t-cell lymphoma (ptcl).

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's drug patent expiration?
More Information on Dosage

BELEODAQ family patents

Family Patents